4D Molecular Therapeutics secured the return of Berkeley Catalyst Fund for a series C round that follows plans for a $100m IPO announced in September 2019.

US-based gene medicine developer 4D Molecular Therapeutics (4DMT) completed a $75m series C round yesterday featuring Berkeley Catalyst Fund, a venture unit aligned with University of California.
The round was led by healthcare-focused hedge fund manager Viking Global Investors and included financial services group MiraeAsset, Chiesi Ventures and Pfizer Ventures, investment vehicles for pharmaceutical firms Chiesi Group and Pfizer.
Cystic Fibrosis Foundation, Amzak Health, Longevity Vision Fund, BVF Partners, Arrowmark Partners, Ridgeback Capital Investments, Perceptive Advisors, Pappas Capital,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?